Merck: This Cancer-Drug Powerhouse Could Be a Core Dividend
A dividend-focused investor might overlook Merck at first glance. Yet this cancer‑drug powerhouse blends steady cash ...
Introductory guidance on choosing long-term holds for beginners, focusing on fundamentals, liquidity, and project viability.
27,784 articlesA dividend-focused investor might overlook Merck at first glance. Yet this cancer‑drug powerhouse blends steady cash ...
A notable insider maneuver at CareDx drew attention to the stock. This article breaks down the sale, what it means fo...
Planning to invest in real estate in 2026? This guide shows how to map goals, choose the right loans, and build a pra...
Policy shifts around president trump's drug pricing could squeeze pharma profits and shift stock dynamics. This guide...
A leading biotech-focused fund just boosted its Immunome position by a material amount as the stock surged. This arti...
Bitcoin neared $70,000 on Coinbase as fresh liquidity returns to risk assets. Analysts describe the move as an analys...
Oil pushes toward $100 a barrel as Bitcoin struggles to extend its rally, with surges near $100 stalling the crypto b...
As the Fed prepares to announce rates on March 18, XRP sits near $1.40. The key driver could be the dot plot, not the...
A major fund just walked away from its Li Auto position, selling roughly $33 million worth of shares in one quarter. ...
A drone strike sparks fire near the UAE's Barakah nuclear plant, prompting swift emergency action. Officials say safe...
Carvana remains a high-risk trade due to debt and cyclical demand. Two safer picks, Kinder Morgan and Regions Financi...
XRP trades around $1.04 after a June lull, as wallet growth and ETF inflows stoke optimism. Analysts caution that a s...